SPCA1 Inhibitors
Chemicals classified as SPCA1 inhibitors would consist of compounds that can affect the activity of the SPCA1 protein, a calcium pump localized to the Golgi apparatus involved in the transport of Ca²⁺ and Mn²⁺ into the Golgi lumen for proper functioning of the secretory pathway. This class of inhibitors, while not directly targeting SPCA1, operates by influencing the cellular pathways and processes that modulate the functionality of SPCA1. These compounds can either disrupt or alter calcium homeostasis or affect related signaling pathways that are crucial for the regulation of SPCA1.
These inhibitors are not specific to SPCA1 but rather exert their effects on a range of targets that are involved in maintaining the calcium balance within the cell, which is a critical determinant of SPCA1's activity. For instance, agents like Bafilomycin A1 and Thapsigargin target proton pumps and SERCA pumps, respectively, leading to changes in calcium concentrations that can secondarily alter SPCA1-mediated calcium transport.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
A specific inhibitor of the V-ATPase proton pump, which could disrupt lysosomal acidification and secondarily affect calcium stores, thus possibly influencing SPCA1 activity due to altered calcium dynamics. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
A sesquiterpene lactone that specifically inhibits the sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase (SERCA), leading to increased cytosolic calcium levels and potentially affecting SPCA1 regulation due to altered calcium homeostasis. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
A modulator of IP3 receptors and store-operated calcium entry, which can alter calcium signaling and potentially influence SPCA1 activity by modifying the cellular calcium balance. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $103.00 $158.00 $397.00 $656.00 | 2 | |
An inhibitor of receptor-mediated calcium entry channels, which may alter calcium homeostasis and indirectly affect SPCA1 activity. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
A modulator of ryanodine receptors on the sarcoplasmic and endoplasmic reticulum, which can modulate calcium release from these stores and potentially influence SPCA1 indirectly. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
An inhibitor of the SERCA pump, leading to altered calcium levels in the cytosol and endoplasmic reticulum, which could influence SPCA1 activity indirectly. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
A calcium channel blocker that primarily affects voltage-gated calcium channels but could also indirectly affect cellular calcium homeostasis and potentially SPCA1 activity. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Similar to verapamil, it is a calcium channel blocker that can indirectly influence cellular calcium levels and thus affect SPCA1 activity indirectly. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
An ionophore that transports calcium across biological membranes, which could disrupt calcium homeostasis and indirectly affect SPCA1 activity. | ||||||